Artiva Biotherapeutics’ (NASDAQ:ARTV – Get Free Report) lock-up period is set to expire on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its IPO on July 19th.
Barclays PLC purchased a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with ...
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 69% phase ...
The Chief Electoral Officer, Delhi, is conducting a Special Summary Revision of electoral rolls with the qualifying date set as January 1, 2025, a statement said on Tuesday, highlighting the CEO's ...
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is a clinical-stage biotechnology company that has captured the attention of investors and analysts alike with its innovative approach to developing natural ...
On Monday, H.C. Wainwright initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and established a price target of $20.00, aligning with the broader analyst consensus of "Strong ...
Hosted on MSN25d
HC Wainwright & Co. Initiates Coverage of Artiva Biotherapeutics (ARTV) with Buy RecommendationAnalyst Price Forecast Suggests 103.71% Upside As of December 23, 2024, the average one-year price target for Artiva Biotherapeutics is $21.68/share. The forecasts range from a low of $18.18 to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback